Vera Therapeutics, Inc. (NASDAQ:VERA) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of Vera Therapeutics, Inc. (NASDAQ:VERA) have earned a consensus recommendation of “Moderate Buy” from the twelve ratings firms that are covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, two have given a hold recommendation and nine have issued a buy recommendation on the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $74.8333.

Several equities research analysts have weighed in on the company. Evercore ISI raised their price target on Vera Therapeutics from $75.00 to $97.00 and gave the stock an “outperform” rating in a report on Monday, December 8th. Wedbush lifted their target price on shares of Vera Therapeutics from $23.00 to $33.00 and gave the stock a “neutral” rating in a research note on Thursday, December 11th. Pivotal Research set a $73.00 price target on shares of Vera Therapeutics in a research note on Friday, December 5th. JPMorgan Chase & Co. lowered their price objective on shares of Vera Therapeutics from $99.00 to $96.00 and set an “overweight” rating for the company in a research note on Friday, December 19th. Finally, Bank of America upped their target price on Vera Therapeutics from $48.00 to $66.00 and gave the company a “buy” rating in a research report on Friday, December 19th.

Insider Activity

In other Vera Therapeutics news, Director Patrick G. Enright purchased 5,882 shares of the business’s stock in a transaction that occurred on Thursday, December 11th. The shares were bought at an average price of $42.50 per share, for a total transaction of $249,985.00. Following the acquisition, the director owned 5,882 shares in the company, valued at $249,985. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, SVP Joseph R. Young sold 15,000 shares of the firm’s stock in a transaction that occurred on Tuesday, November 11th. The stock was sold at an average price of $29.06, for a total transaction of $435,900.00. Following the transaction, the senior vice president directly owned 47,839 shares of the company’s stock, valued at $1,390,201.34. This represents a 23.87% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 16.30% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in VERA. Vestal Point Capital LP lifted its position in Vera Therapeutics by 24.0% during the second quarter. Vestal Point Capital LP now owns 3,100,000 shares of the company’s stock valued at $73,036,000 after purchasing an additional 600,000 shares during the period. Integral Health Asset Management LLC raised its stake in shares of Vera Therapeutics by 47.8% during the 3rd quarter. Integral Health Asset Management LLC now owns 1,700,000 shares of the company’s stock valued at $49,402,000 after buying an additional 550,000 shares during the last quarter. Braidwell LP acquired a new position in shares of Vera Therapeutics in the 3rd quarter valued at about $13,738,000. Capricorn Fund Managers Ltd purchased a new stake in shares of Vera Therapeutics in the third quarter worth about $13,097,000. Finally, Armistice Capital LLC boosted its stake in shares of Vera Therapeutics by 294.1% in the third quarter. Armistice Capital LLC now owns 536,000 shares of the company’s stock worth $15,576,000 after buying an additional 400,000 shares during the last quarter. Hedge funds and other institutional investors own 99.21% of the company’s stock.

Vera Therapeutics Price Performance

NASDAQ VERA opened at $43.26 on Friday. The firm’s fifty day simple moving average is $45.88 and its two-hundred day simple moving average is $32.54. The firm has a market capitalization of $2.77 billion, a P/E ratio of -10.84 and a beta of 1.16. The company has a current ratio of 12.21, a quick ratio of 12.21 and a debt-to-equity ratio of 0.19. Vera Therapeutics has a 12-month low of $18.53 and a 12-month high of $56.05.

Vera Therapeutics (NASDAQ:VERA) last issued its quarterly earnings data on Wednesday, November 5th. The company reported ($1.26) EPS for the quarter, missing the consensus estimate of ($1.20) by ($0.06). During the same quarter in the previous year, the firm posted ($0.85) earnings per share. Analysts forecast that Vera Therapeutics will post -2.89 EPS for the current fiscal year.

About Vera Therapeutics

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.